Drug-Coated Balloon Angioplasty Stent for Coronary Lesions
Drug-Coated balloons Show Promise as Alternative to Stents for Certain Heart Conditions
Table of Contents
Published October 27, 2025, at 08:05 AM
New research suggests that drug-coated balloons (DCBs) offer a safe alternative to conventional drug-eluting stents (DES) for patients with newly diagnosed, uncomplicated coronary artery disease. While a recent trial didn’t definitively prove DCBs were non-inferior to stents – meaning they weren’t shown to be equally as effective – the study revealed remarkably low rates of adverse events with DCB use, offering a potential benefit for select patients.
the REC-CAGEFREE I Trial: A Closer Look
The study, an open-label, randomized, non-inferiority trial, focused on individuals with de novo (newly developed) and non-complex coronary lesions. Researchers compared outcomes between patients treated with DCBs and those receiving DES. Although the DCB group didn’t meet the pre-defined criteria for non-inferiority, the overall event rates at two years were encouragingly low in both groups.
Crucially, the research highlighted the safety profile of DCB-only angioplasty. There were zero instances of acute occlusion – complete blockage of the artery during the procedure – in the DCB group,compared to one case in the DES group. Moreover,the rate of vessel thrombosis (blood clot formation within the artery) was exceptionally low in both groups: 0.4% for those treated with DCBs and 0.3% for those receiving stents.
What This Means for Patients
For years, drug-eluting stents have been the standard of care for opening blocked coronary arteries. These small, mesh tubes are inserted during angioplasty to keep the artery open and prevent re-narrowing. However,stents require patients to take antiplatelet medications (blood thinners) for an extended period – often a year or more - to prevent clots from forming on the stent surface. This long-term medication use can increase the risk of bleeding.
DCBs, conversely, deliver medication directly to the artery wall during angioplasty, potentially reducing the need for prolonged antiplatelet therapy. The low rates of occlusion and thrombosis observed in the REC-CAGEFREE I trial suggest that DCBs can be a safe option, particularly for patients who may be at higher risk of bleeding or who prefer to avoid long-term medication.
Future Directions
While the REC-CAGEFREE I trial provides valuable insights, further research is needed to fully understand the long-term benefits and risks of DCBs compared to stents. Ongoing studies are investigating the use of DCBs in more complex lesions and in different patient populations. The goal is to refine patient selection criteria and optimize treatment strategies to maximize the benefits of this promising technology.